This week I moderated a webinar at the Meals & Drug Law Institute (FDLI) on the regulation of cannabis-derived solutions. This is a solution & policy location that is evolving as I sort. Just this week, former FDA Commissioner Scott Gottlieb wrote an op-ed acknowledging the customer “craze” for solutions with CBD in them and encouraging FDA to regulate these solutions in a manner that frequently enables them to keep on the market place in the imply time.
It is difficult, even though, to place news like this into context if you do not know the distinction amongst cannabis, hemp, marijuana, and CBD (which is brief for “Cannabidiol”) or who regulates them, and beneath what sort of framework. This concern location is notable for the quantity of government actors that are in the mix (e.g., foreign governments, and federal, state, and nearby regulators). In the federal executive branch alone, DOJ (specifically DEA), USDA, FDA, and NIH all play big roles.
Our webinar offers newcomers a crash course on definitions, the brain science of cannabis, and the big U.S. regulators and their frameworks, as effectively as a short remedy of international and state/nearby considerations. It is a great location to begin if you need to have an orientation into this fascinating and quickly evolving location.
Right here are the presenters:
Will Garvin, Shareholder, Buchanan Ingersoll & Rooney Computer
Aidan Hampson, Particular Content material Professional Cannabis, National Institute on Drug Abuse (element of NIH)
Jonathan Havens, Companion, Chair of Meals & Beverage Practice, Co-Chair of Cannabis Law Practice, Saul Ewing Arnstein & Lehr LLP
Larry Houck, Director, Hyman, Phelps & McNamara, Computer
Moderated by Bridget Dooling, Study Professor, George Washington University
Come to this concern location for its relevance to pop culture, but keep for the regulatory puzzles that lie inside. A recording is out there for a charge ($99 for FDLI members, $199 for non-members) through FDLI’s web-site.